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Abstract
Background: Recombinational systems have been developed to rapidly shuttle Open Reading
Frames (ORFs) into multiple expression vectors in order to analyze the large number of cDNAs
available in the post-genomic era. In the Creator system, an ORF introduced into a donor vector
can be transferred with Cre recombinase to a library of acceptor vectors optimized for different
applications. Usability of the Creator system is impacted by the ability to easily manipulate DNA,
the number of acceptor vectors for downstream applications, and the level of protein expression
from Creator vectors.
Results: To date, we have developed over 20 novel acceptor vectors that employ a variety of
promoters and epitope tags commonly employed for proteomics applications and gene function
analysis. We also made several enhancements to the donor vectors including addition of different
multiple cloning sites to allow shuttling from pre-existing vectors and introduction of the lacZ alpha
reporter gene to allow for selection. Importantly, in order to ameliorate any effects on protein
expression of the loxP site between a 5' tag and ORF, we introduced a splicing event into our
expression vectors. The message produced from the resulting 'Creator Splice' vector undergoes
splicing in mammalian systems to remove the loxP site. Upon analysis of our Creator Splice
constructs, we discovered that protein expression levels were also significantly increased.
Conclusion: The development of new donor and acceptor vectors has increased versatility during
the cloning process and made this system compatible with a wider variety of downstream
applications. The modifications introduced in our Creator Splice system were designed to remove
extraneous sequences due to recombination but also aided in downstream analysis by increasing
protein expression levels. As a result, we can now employ epitope tags that are detected less
efficiently and reduce our assay scale to allow for higher throughput. The Creator Splice system
appears to be an extremely useful tool for proteomics.
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Background
After the publication of the human genome in 2001
([1,2]), the focus shifted from gene identification to
understanding the function of the identified gene prod-
ucts. Although the human genome project predicted and
annotated genes, cDNAs for experimental use were still
only available in small numbers. Thus, a number of large
scale human cDNA cloning projects were established
including MGC ([3])[4], Kazusa ([5])[6], Nedo [7,8], and
the German Human cDNA project [9]. The availability of
these cDNA collections has facilitated rapid progress in
the study of the human proteome. These cDNAs, however,
contain 5' and 3' untranslated regions (UTRs) that pre-
clude using them directly to make fusion proteins for
downstream applications. Thus, several groups are creat-
ing human open reading frame (ORF) libraries, including
the Harvard Institute of Proteomics and the Vidal lab at
Harvard (reviewed in [10,11]). These large scale ORF
cloning efforts and other smaller projects employ in vitro
recombination cloning to allow rapid DNA shuttling
between a storage vector and various expression vectors
that add 5' or 3' sequences that encode epitope tags or pro-
teins which enable investigation of protein function.
Elledge developed the first recombination system using
the Cre recombinase ([12]), the non-commercial Univec-
tor system. The two most widely used commercial recom-
binational systems are the Gateway system by Invitrogen
and the Creator system from Clontech, which are gener-
ally used by the large scale cDNA cloning programs.
The Creator system requires only the Cre recombinase
from Bacteriophage P1 and loxP, its recognition sequence,
for the recombination reaction ([13], reviewed in [10]).
Initially, ORFs are cloned between two loxP sites in a
donor vector. Then, sequences flanked by these two loxP
sites are recombined by Cre recombinase into a single
loxP site on an acceptor vector. However, the recombina-
tion site is regenerated during the reaction leading to
undesirable downstream products. To circumvent this
problem, the correct clone is selected by employing a pos-
itive/negative selection scheme. Any recombinant vector
that still retains the donor backbone is negatively selected
due to the presence of the sacB gene from Bacillus subtilis
that is lethal to E. coli when its substrate, sucrose, is added
to the media [14,15]. The desired recombinant vector is
positively selected by reconstitution of the Chloramphen-
icol resistance (CmR) gene when the CmR ORF on the
donor vector properly aligns with the CmR promoter on
the acceptor vector. In mammalian cells, a splicing event
engineered into the Creator system removes the CmR
gene to allow for 3' tagging.
Our laboratory chose the Creator system as our primary
recombinational system because of its ready adaptability,
minimal cost, and performance. We subsequently
enhanced this system to better suit the requirements of
our laboratory. First, to allow for easy cloning of ORFs
into donor vectors, we modified the multiple cloning site
on the donor vector to possess two restriction endonucle-
ase sites that occur infrequently in mammalian cDNAs.
Second, various acceptor vectors were created to facilitate
different expression technologies for proteomics applica-
tions. Lastly, mammalian pre-mRNA splicing sequences
were introduced into the vectors so that linker sequences
between 5' tags and the ORFs would be removed upon
pre-mRNA processing. We term this new system 'Creator
Splice'. Interestingly, the addition of an intron at the 5'
end increased overall expression, probably due to better
processing of the mRNA. These new adapted vectors are a
good resource for common proteomic applications.
Results
Optimization of the Creator recombination reaction
To facilitate high-throughput ORF manipulation, a cost-
effective and robust method of DNA transfer is para-
mount. The recombination between loxP sites in the Cre-
ator system is executed by only one protein (Cre). Since
Cre enzyme can be readily produced in a typical labora-
tory, employment of the Creator system can result in sig-
nificant cost savings. From a 600 ml starting bacterial
culture expressing His-tagged Cre, enough enzyme was
purified to perform over 20,000 reactions. While testing
the His-Cre enzyme, we discovered that altering the
recombination buffer composition had a marked effect on
the number of colonies recovered after transformation of
the Cre reaction into bacteria – a step that is traditionally
inefficient. By using the optimized buffer (see methods),
the number of colonies after transformation increased
greater than 5 fold over the standard buffer (data not
shown).
Modification of donor vectors
To reduce the cost and increase the efficiency of moving
ORFs into the Creator donor vectors, several changes were
made to the donors. The multiple cloning site (MCS) of
donor pDNR Dual vector (Clontech) does not contain
any rare-cutting restriction enzyme sites. Accordingly, we
were unable to standardize cloning protocols using the
traditional ligation route since the restriction enzyme sites
in the MCS of the donor vector are often present in ORF
sequences. Thus, the MCS of pDNR Dual was altered to
add an AscI site to the 5' end and a PacI site to the 3' end
(Figure 1A). These two sites were chosen for several rea-
sons. First, the 8-base recognition sites for both enzymes
occur infrequently (95 % of 25,000 mouse cDNAs exam-
ined did not contain recognition sites for either of these
enzymes). Second, AscI and PacI are compatible in the
same restriction enzyme buffer and do not exhibit star
activity. Third, both enzymes are active against various
forms of DNA including linear, supercoiled and bacteri-BMC Biotechnology 2006, 6:13 http://www.biomedcentral.com/1472-6750/6/13
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Description of vectors for the Creator and Creator Splice systems Figure 1
Description of vectors for the Creator and Creator Splice systems. A) Schematic of the donor vector illustrating the essential 
features of the donor vector. ORFs are cloned into the Multiple Cloning Site (MCS) that is flanked by two loxP sites. The CmR 
ORF following the MCS, but still within the two loxP sites, ensures that both the ORF cassette from the donor vector and the 
acceptor vector backbone (containing the CmR promoter) are retained in the final product. The ampicillin resistance gene 
(AmpR) provides positive selection and the SacB gene imparts negative selection (against the donor backbone). Sequences of 
the novel MCS for the modified Creator and Creator Splice vectors are indicated below the diagram. The MCS starts at the 
AscI site and ends at the PacI site. The last four nucleotides of the loxP site are shown for orientation. The splice acceptor 
sequence in the Creator Splice vector is shown in green to emphasize the difference between the two vectors. B) A schematic 
of the modular nature of the acceptor vectors. The types of cassettes (promoter, tags, selectable markers) that can be inter-
changed to create vectors for specific proteomics needs are illustrated, not all combinations are available (Table 2). Abbrevia-
tions: AmpR – ampicillin resistance gene, b – bacteria expression, CmR – chloramphenicol resistance ORF, i – insect 
expression, m – mammalian expression, MCS – multiple cloning site, SA – splice acceptor.
AmpR
CmR ORF
MCS loxP
SacB
loxP
Generic Donor Vector
loxP Splice Acceptor AscI
TTA TGG CGC GAG GGT TTC CTT GAC AAT ATC ATA CTT ATC CTG TCC CTT TTT TTT CCC CAG GGG
SalI NdeI SmaI EcoRI PstI BamHI XhoI
CGC GCC GTC GAC GGT ACC GGA CAT ATG CCC GGG AAT TCC TGC AGG ATC CGC TCG AGA
HindIII XbaI BstXI BssHII ApaI PacI SD AvrII
AGC TTT CTA GAC CAT TCG TTT GGC GCG CGG GCC TTAATT AAC CAG GTAAGTTCCTAGG
Multiple Cloning Site for Creator Splice Donor V37 (pDNR MCS SA)
loxP AscI SalI NdeI SmaI EcoRI PstI BamHI XhoI
TTA TGG CGC GCC GTC GAC GGT ACC GGA CAT ATG CCC GGG AAT TCC TGC AGG ATC CGC TCG
HindIII XbaI BstXI BssHII ApaI PacI SD AvrII
AGAAGC TTT CTA GAC CAT TCG TTT GGC GCG CGG GCC TTAATT AAC CAG GTAAGTCCTAGG
Multiple Cloning Site for Creator Donor V7 (pDNR MCS)
A)
B)
Acceptor Vector
Promoters
CMV (m)
LTR (m)
Tac (b)
Trc (b)
polyhedrin (i)
Tags
ECFP
EGFP
EYFP
Flag
triple-Flag
GST
GST His
HA
His
double-Myc
RFP
Tags
ECFP
ECFP-mito
EGFP
EYFP
Flag
triple-Flag
GST
GST His
HA
His
double-Myc
RFP
RFP-mito
Markers
ampicillin (b)
kanamycin (b)
G418/neomycin (m)
puromycin (m)
loxPBMC Biotechnology 2006, 6:13 http://www.biomedcentral.com/1472-6750/6/13
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ally methylated DNA (neither site contains a methylation
sequence). Fourth, both enzymes digest DNA at a non-
degenerate and non-interrupted recognition site and
cleavage results in a 5' or 3' DNA overhang. Fifth, both
enzymes efficiently cleave DNA from a wide variety and
quality of preparations. Sixth, AscI has a strong consensus
to the Kozak sequence needed for mammalian expression
(GCGCC vs. CCACC) [16,17]. Therefore, it was not neces-
sary to add additional sequences to each construct to con-
form to the Kozak consensus. Lastly, the PacI site contains
stop codons for the two non-reading frames. The resulting
vector, that also removes a hexa-histadine tag at the C-ter-
minus, is called pDNR MCS (V7) (Table 1). In addition,
we have constructed other donor vectors with different
multiple cloning sites: pDNR MCS BE (V624) with
BamHI, SmaI, and EcoRI sites compatible with pGEX
series vectors (Amersham) and pDNR MCS ES (V795)
with EcoRI, NotI and SalI sites (Table 1). We also inserted
the lacZ alpha sequence into the MCS of our donor vec-
tors (V308, V677). The lacZ alpha sequence reduces the
time to screen for positive clones as blue colonies indicate
undigested wildtype vector.
Acceptor vector construction
The utility of recombinational cloning systems lies in the
availability of acceptor vectors for the tasks at hand. To
this end, we have created over 20 acceptor vectors with
different tags, promoters, and resistance markers (Figure
1B). For expression of proteins in mammalian cells that
can be easily purified by immunoprecipitation, visualized
in lysates by immunoblot analysis or in cells by immun-
ofluorescence, we have created vectors containing the fol-
lowing epitope tags: Single and Triple-Flag, Double-Myc,
and HA (Table 2). In addition, we inserted a cassette con-
taining a 5' Triple-Flag tag and loxP site into the pMSCV
retrovirus vector. For expression in non-mammalian cells,
we created acceptor vectors for both bacterial (GST or His
tags) and baculoviral expression (GST and His tag). For
localization using proteins fused to fluorescent proteins,
we use vectors pLP ECFP C1 (enhanced cyano), pLP EGFP
C1 (enhanced green), pLP EYFP C1 (enhanced yellow)
and pLPS-3'EGFP and we also created a 3' ECFP vector. To
expand our repertoire of fluorescent proteins, we mutated
the red fluorescent protein gene from Clontech (dsRED2)
to increase the fluorescent intensity and prevent
homodimerization of the resulting red fluorescent protein
(RFP) [18,19]. Acceptor vectors containing both 5' and 3'
RFP have subsequently been created. We also constructed
vectors that fuse a fluorescent protein and the mitochon-
drial targeting sequence of Listeria monocytogenes ActA pro-
tein (Mito tracker) ([20]) to the COOH terminus of the
expressed insert. Proteins fused at their COOH terminus
to the Mito tracker are re-located to the mitochondria
([21,22]). In Figure 2, the first 240 amino acids of the pro-
tein Angiomotin fused at the C-terminus to ECFP dis-
played a cytoplasmic expression (top panel). However,
when the same protein sequence was fused to the ECFP-
mito tracker, it was redirected to the mitochondria and co-
localized with Cytochrome C (bottom panel). This vector
can be used to verify protein-protein interactions in vivo
by demonstrating that the re-localization of one protein
leads to the re-localization of its partner(s). For example,
the SH3 domain of TUBA when fused to the mito tracker
will recruit actin to the mitochondria [22]. In addition,
recruitment of the partner(s) away from their endogenous
location may lead to phenotypic consequences for the cell
that can aid functional interpretation.
Addition of splice sites to the Creator system (Creator 
Splice)
One issue with recombinational systems is the large linker
between the tag and the ORF after recombination due to
the recombination site and other intervening sequences.
For 5' tags in the Creator system, the linker size can be
between 51 to 81 nucleotides (17–27 codons) depending
on which two vectors are recombined. In contrast, the
splicing event employed for 3' tags to remove the CmR
gene can introduce as little as 21 nucleotides (7 codons).
Table 1: donor vectors constructs
Vector ID Vector Name Potential Splicing Events Description
V1 pDNR Dual Splice for 3' tags Designed for Fusions at both N- and C- termini (Clontech)
V7 pDNR-MCS Splice for 3' tags Alternate MCS that adds AscI and PacI sites to the MCS of V1
V37 pDNR MCS SA Splice for 5' and 3' tags A splice acceptor introduced into V7 before the AscI site
V308 pDNR MCS lacZ alpha Splice for 3' tags LacZ alpha inserted between AscI and PacI sites of V7
V309 pDNR MCS SA lacZ alpha Splice for 5' and 3' tags LacZ alpha inserted between AscI and PacI sites of V37
V624 pDNR MCS BE Splice for 3' tags Alternate MCS with BamHI, SalI, SmaI, HindIII, EcoRI sites
V677 pDNR MCS BE lacZ alpha Splice for 3' tags LacZ alpha inserted between SalI and HindII sites of V624
V678 pDNR MCS SA ES Splice for 5' and 3' tags Alternate MCS Splice Acceptor with AscI, EcoRI, NotI, BamHI, SalI, PacI 
sites.
V795 pDNR MCS ES Splice for 3' tags Alternate MCS with AscI, EcoRI, NotI, BamHI, SalI, PacI sites
V954 pDNR MCS SA no SA CmR Splice for 5' and 3' tags Silent mutations introduced in the CmR ORF of V309 to remove 
potential splice acceptor
*Abbreviations used: SA – splice acceptor, MCS – multiple cloning site, CmR – chloramphenicol resistance, BE – BamHI/EcoRI, ES – EcoRI/SalIBMC Biotechnology 2006, 6:13 http://www.biomedcentral.com/1472-6750/6/13
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To reduce the linker size for 5' tags, we added splicing sig-
nals similar to that utilized for 3' tags. In order to have a
functional intron after recombination, the 3' splice accep-
tor sequence must come from the donor vector and the 5'
splice donor and intron sequences must come from the
acceptor vector (Figure 1A and 3). For the 5' intron, we
selected 360 nucleotides from the Adenovirus L1 major
late intron before the 2nd leader. This intron does not
undergo alternative splicing, does not contain any poten-
tial splice donors or splice acceptors, and is unlikely to
contain sequences that would reduce splicing efficiency
(analyzed by BDGP splice site prediction [23,24]). We
purposely chose a small intron size because smaller
introns tend to be more abundant in higher expressed
mRNAs [25]. For the donor vectors, we added splice
acceptor sequences preceding the MCS (V37, V309, V678,
V694, Figure 1A, Table 1). We also chose the splice accep-
tor from the same Adenovirus major late intron used
above. Both the splice donor and splice acceptor
sequences have maximal scores for splice site consensus
sequences as defined by the BDGP splice site prediction
algorithm. Upon recombination and expression in mam-
malian cells, the resulting pre-mRNA will undergo splic-
ing (Figure 3). The amount of sequence between the tag
and the resulting protein is now reduced to between 3 and
5 amino acids in the Creator Splice system depending on
the vectors recombined. Three potential splice acceptor
sites were also identified using the BDGP splice site algo-
rithm in the CmR ORF. Since these cryptic sites might
reduce protein levels when using a C-terminal tag, we con-
structed a new vector that introduced silent mutations in
the CmR ORF to remove the two strongest potential sites
(V954). However, removal of these sites did not increase
protein levels of 3' tags as analyzed by immunoblot anal-
ysis (data not shown).
Expression of constructs in mammalian cells
While the ease of rapidly shuttling a particular ORF into
various vectors is a major merit of in vitro recombination
systems, protein expression levels from the resulting
expression vectors must be sufficiently high for the
desired assays. To analyze the expression levels of various
acceptor vectors, immunoblot analysis was performed on
cell lysates. In Figure 4A, two different proteins (WWP2
and BulI) fused to Double-Myc tags were expressed in
HEK293T cells by transient transfection. In this assay, we
tested three different tag positions: SPLICE (splicing at 5'
end), 5' (no splicing) and 3' (splicing at 3' end to remove
the CmR gene). Full-length proteins at the expected sizes
were recognized by the Myc antibody 9E10 in all three
combinations of tags for both ORFs. Interestingly, the
Creator Splice system appeared to have the highest pro-
tein expression levels.
To further test our system and to ensure that Creator and
Creator Splice systems are compatible, we expressed pro-
teins fused to Triple-Flag epitopes from vectors derived
from various recombinations. In addition to examining
the three different tag positions analyzed above, we added
two more combinations. First, we wanted to confirm that
the donor vectors from the Creator Splice system could
express proteins when recombined with acceptor vectors
from the regular Clontech Creator system (Figure 4B,
labeled 5' SA). In these recombinants, the splice acceptor
sequence in the donor vector is not removed leading to an
extra 18 amino acids between the tag and the ORF. Sec-
ond, we wanted to ensure that the Creator Splice donor
vectors did not interfere with protein expression when
using tags at the 3' end (Figure 4B, labeled 3' SA). To these
ends, immunoblot analysis was performed on HEK293T
cell lysates after transfection with the indicated constructs
(Figure 4B). All combinations of tags resulted in full-
length protein expression. Therefore, vectors from the
Clontech Creator and Creator Splice Systems can be inter-
changed if necessary. Of note, for the vectors tested in this
assay, expression levels of proteins ArhGEF9 and ArhGEF1
seemed highest from the Creator Splice vectors (labeled
SPLICE, Figure 4B).
To confirm that the Creator Splice system displays supe-
rior expression levels, we tested 6 different ORFs for differ-
ences in protein expression between the Clontech Creator
system, the Creator Splice system, and the Topoisomerase
system (Invitrogen, [26]) all using a Triple-Flag epitope as
the tag. HEK293T cells were transiently transfected with
the indicated constructs and immunoblot analysis with
the Flag M2 antibody was performed on the lysates. Rep-
resentative gels of two proteins (ArhGap24 and Nadrin)
are displayed in Figure 5A and 5B. Similar to the results
using Double-Myc epitope tags, the Creator Splice system
appeared to have the highest levels of expression of the
Creator constructs and was comparable to expression
from the non-recombinational Topoisomerase vector.
One possibility that could account for the differences in
expression seen between the 5' Creator tags is that the loxP
site is masking to some extent the ability of the epitope to
be recognized by the Flag antibody. To test this possibility,
we re-probed the anti-Flag immunoblot of Nadrin with an
antibody specific to Nadrin (Figure 5B, bottom panel).
The Nadrin antibody detects more protein from the Crea-
tor Splice construct (SPLICE) than from the 5' Clontech
Creator constructs indicating that differences in epitope
detection cannot account for the differences in protein
expression.
To quantitate protein expression levels, the band intensity
of the tagged proteins, as detected by anti-M2 Flag anti-
body, was analyzed. Only the band corresponding to the
size of the full-length protein is quantitated. To control forBMC Biotechnology 2006, 6:13 http://www.biomedcentral.com/1472-6750/6/13
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transfection efficiency, the vector pLP-ECFP C1 that
expresses ECFP was co-transfected with the test expression
vectors, and the amount of fluorescence in the cell lysates
was measured. This control will normalize for differences
in transfection levels as well as differences in cell count
and lysate volume. A bar chart of the expression levels of
various constructs normalized by fluorescence levels is
shown in Figure 5C. Only constructs expressed in the Cre-
ator Splice system were comparable with constructs
cloned via the non-recombination Topoisomerase sys-
tem. Thus, it appears that the additional sequences intro-
duced by the loxP site in the original Clontech Creator
system vectors may reduce expression levels.
Discussion
We describe here several improvements on the Creator
recombinational cloning system that will facilitate the use
of the increasingly large number of cDNAs available for
proteomics applications. In the Creator System, a DNA
fragment can be introduced into the donor vector by
standard restriction enzyme digestion and ligation or by
the In Fusion recombination method (Clontech). The lat-
ter method is used by the large scale cloning laboratory at
the Harvard Institute of Proteomics (HIP) for the creation
of their FLEX Gene libraries ([10]). While we have used
this method to clone into donor vectors with similar suc-
cess as HIP, it is our system of choice only for inserts larger
Table 2: acceptor vectors constructs
Vector ID Vector Name Potential 
Splicing Events
Tag Tag Position Promoter Function Expression 
Verification
V3 pLP-ECFP C1 
(Clontech)*
none ECFP N-terminus CMV localization Verified by Clontech
V4 pLP-EGFP C1 (Clontech) none EGFP N-terminus CMV localization Verified by Clontech
V5 pLP-EYFP C1 (Clontech) none EYFP N-terminus CMV localization Verified by Clontech
V6 pLPS-3'EGFP (Clontech) Splice for 3' Tags EGFP C-terminus CMV localization Verified by Clontech
V956 pLPS-3'ECFP Splice for 3' Tags ECFP C-terminus CMV localization Figure 3
V957 pLPS-3'ECFP-mito Splice for 3' Tags ECFP-mito C-terminus CMV targets to 
mitochondria
Figure 3
V1662 pLP-RFP none RFP N-terminus CMV localization Additional File 5A
V1663 pLPS-3'RFP Splice for 3' Tags RFP C-terminus CMV localization Verified, Data not 
Shown
V1664 pLPS-3'RFP-mito Splice for 3' Tags RFP-mito C-terminus CMV targets to 
mitochondria
Verified, Data not 
Shown
V25 pLP Flag none Flag N-terminus CMV IP/IB/IF Additional File 5C
V26 pLPS-3'Flag Splice for 3' Tags Flag C-terminus CMV IP/IB/IF Additional File 5B
V33 pLP Flag SD Splice for 5' Tags Flag N-terminus CMV IP/IB/IF Additional File 5C
V179 pLP Triple-Flag none Triple-Flag N-terminus CMV IP/IB/IF Figure 4&5
V180 pLP Triple-Flag SD Splice for 5' Tags Triple-Flag N-terminus CMV IP/IB/IF Figure 4&5
V181 pLPS 3' Triple-Flag Splice for 3' Tags Triple-Flag C-terminus CMV IP/IB/IF Figure 4&5
V207 pRETRO-Triple-Flag SD Splice for 5' Tags Triple-Flag N-terminus LTR IP/IB/IF/
retrovirus%
Additional File 5D
V143 pLP-HA SD Splice for 5' Tags HA N-terminus CMV IP/IB/IF Additional File 5E
V27 pLPS-3'HA Splice for 3' Tags HA C-terminus CMV IP/IB/IF Not expression 
verified
V516 pLP-dMyc none Double-Myc N-terminus CMV IP/IB/IF Figure 4
V517 pLP-dMyc SD Splice for 5' Tags Double-Myc N-terminus CMV IP/IB/IF Figure 4
V518 pLPS-3'dMyc Splice for 3' Tags Double-Myc C-terminus CMV IP/IB/IF Figure 4
V621 pGEX-4T-LP none GST N-terminus Tac Bacteria 
expression
Verified, Data not 
Shown
V622 pGEX-2TK-LP none GST N-terminus Tac Bacteria 
expression
Additional File 5F
V623 pAcGHLT-LP none GST His N-terminus Ph Baculovirus 
expression
Not expression 
verified
V1579 pLP ProHis HTb none His N-terminus Trc Bacteria 
expression
Additional File 5G
*Abbreviations used: LP – loxP, mito – mitochondria localization peptide, SD – splice donor, IP – immunoprecipitation, IB – immunoblot analysis, IF 
– immunofluorescence, Ph – polyhedrin
%V207 has been used extensively to produce protein from transient or stably transfected cells. It has not been tested for retrovirus production or 
resulting protein expression from a retrovirus.BMC Biotechnology 2006, 6:13 http://www.biomedcentral.com/1472-6750/6/13
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than 3 kilobases or those with internal AscI or PacI sites.
The In Fusion method requires longer oligonucleotides
than traditional ligation reactions, more expensive rea-
gents (In Fusion versus restriction enzymes), and is prone
to high background if the digested vector preparation is
contaminated or if digestion is incomplete. For this rea-
son, we altered the donor vector to incorporate AscI and
PacI sites – rare base cutters that would allow us to use the
ligation system of cloning in the majority of cases and In
Fusion recombination for the exceptions.
The interest in any recombination system will increase as
more downstream applications become compatible with
the system. To that end, we have made 22 acceptor vectors
and are continually increasing our repository. While we
have made vectors for expression in bacteria and insect
cells, our primary focus is on mammalian expression and
protein function analysis. As seen in Figure 1B, the accep-
tor vectors are modular such that sequences for epitope
tags, selectable markers, promoters, and expression sys-
tems can be interchanged. One example of an acceptor
vector is based on a concept employed by the Gertler lab
where a protein of interest is fused both to a fluorescent
protein and the mitochondria tracking peptide from L.
monocytogenes ActA protein. Proteins fused to this peptide
are targeted to the mitochondria (Figure 2, [20,22]). Of
interest, proteins that bind to the re-targeted protein can
also be relocated demonstrating an in vivo interaction and
possibly leading to phenotypic consequences that can aid
in the analysis of protein function [22].
One major advantage of the Creator Splice system
described here over the Creator and Gateway recombina-
tional systems is the reduction in linker sequences
between the tag and protein. Although we deleted extrane-
ous sequences in the donor and acceptor vectors when-
ever possible, the major reduction in linker size was via
splicing. The Creator Splice system reduces the amount of
linker to 3 to 5 amino acids, similar to that introduced
between tags and proteins in a typical restriction enzyme/
ligation protocol. Since the linker sequence is so small, it
is possible to add additional sequences to the acceptor
vectors to create the most appropriate linker for down-
stream applications.
When we compared the Creator Splice system against the
standard Clontech Creator system, the Creator Splice sys-
tem had the highest levels of protein expression. A likely
explanation for these increased expression levels is the
presence of the 5' intron. There is accumulating evidence
that pre-mRNAs containing introns are expressed at
higher levels than pre-mRNAs that lack introns [27-30].
Processes involved in mRNA maturation are highly inter-
dependent and the presence of introns influences tran-
scription, polyadenylation, nuclear export and translation
[31]. Early steps in the mRNA maturation pathway affect
later processing steps by imprinting information on the
transcript via protein binding (reviewed in [31,32]. The
exon junction complex (EJC), a splicing-dependent com-
plex, is deposited upstream of exon-exon junctions
[33,34]. Quantitative analysis of intron effects has dem-
onstrated that more protein is produced per transcript
when the transcript has undergone splicing and this
increase is dependent on the EJC [28,35-37]. Therefore,
the increased protein expression seen with the Creator
The Mito tracking peptide targets proteins to the mitochon- dria Figure 2
The Mito tracking peptide targets proteins to the mitochon-
dria. NIH 3T3 cells were transiently transfected with vectors 
expressing either the N-terminus of Angiomotin fused to a 
C-terminal ECFP (top panel) or the same protein fused to a 
C-terminal ECFP plus a mitochondrial tracking peptide 
(ECFP-mito) (bottom panel). The cells were fixed and stained 
with anti-ECFP (green colour in merge) that recognizes the 
fusion construct or anti-Cytochrome C (red colour in 
merge) to mark the mitochondrial membrane. DNA is 
stained with Hoescht (blue colour in merge). The bottom 
right image on both panels is a composite of all three stain-
ings. Note that only transfected cells will display ECFP stain-
ing. Abbreviations – mito – Mito tracker, Cyt C – 
Cytochrome C, ECFP – enhanced cyano fluorescent protein.BMC Biotechnology 2006, 6:13 http://www.biomedcentral.com/1472-6750/6/13
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Schematic of a typical recombination reaction in the Creator Splice system Figure 3
Schematic of a typical recombination reaction in the Creator Splice system. The SD/intron, shown in purple, is the only differ-
ence between a Creator Splice acceptor and a standard acceptor vector. A Creator Splice donor and acceptor are recombined 
in the presence of Cre recombinase in vitro. An intron is formed in the resulting expression vector starting from the SD/intron 
supplied by the acceptor and ending with the splice acceptor from the donor vector. Upon transfection and transcription in 
mammalian cells, the intron is removed and the tag is juxtaposed onto the ORF. Abbreviations: bac – bacteria promoter, CmR 
– Chloramphenicol resistance ORF, kan/neoR – kanamycin and neomycin resistance gene, P – promoter, SA – splice acceptor, 
SD – splice donor.
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Splice system is likely due to more efficient processing of
the mRNA.
Interestingly, Creator clones with 3' tags also utilize splic-
ing to remove the CmR gene. However, we see reduced
expression of these 3' tags as compared to 5' tags in the
Creator Splice system. This reduction might result from
differences in sequence and position of the introns used
for the 5' and 3' tags. Even in identical positions, two dis-
tinct introns can have markedly different effects on gene
expression [38]. The intron chosen for the Creator Splice
system is a bona fide intron from Adenovirus that has
likely evolved to be very effectively spliced, in contrast to
the longer engineered intron for the 3' tag that contains
the CmR gene. We also identified three potential splice
acceptors in the CmR ORF that may lead to undesirable
splice products, although removal of two of these sites did
not alter subsequent protein expression levels. Lastly, the
position of the intron can also highly impact protein
expression levels and introns proximal to the 5' end
enhance transcriptional activity [39,28,40,41].
Proteins produced from Creator vectors with 5' tags
(unspliced) express at lower levels than those produced
from a topoisomerase vector with the same 5' tag. This
result is mirrored in bacteria where the loxP site is delete-
rious to protein expression (for example, see Additional
File 5F &5G). This decrease may be due to the extra 34
nucleotides of the loxP site in the linker. Alternately, the
hairpin secondary structure of loxP (predicted by mFold,
[42,43]) may cause the transcription or ribosomal
machinery to stall in bacteria [44]. In mammalian cells,
the effect that the hairpin would have on mRNA from 5'
tagged constructs is not obvious since it is downstream of
the initiation codon and would be unlikely to inhibit the
ribosomal complex once bound to RNA [45]. Interest-
ingly, the presence of a loxP hairpin upstream of the start
codon in mRNA from 3' tagged constructs could adversely
Protein expression levels in the Creator and Creator Splice system Figure 4
Protein expression levels in the Creator and Creator Splice system. The indicated constructs were transiently transfected into 
HEK293T cells. After 48 hours, the cells were lysed and the lysate subjected to immunoblot analysis. A) WWP2 and BulI fused 
to Double-Myc epitope tags were detected by Myc antibody 9E10. B) ArhGEF9 and ArhGEF1 fused to Triple-Flag tags were 
detected by Flag antibody M2. Abbreviations: 5' SA – Vector created by recombining a Creator Splice donor vector, (splice 
acceptor at 5' end – V37-based), with a 5' tag acceptor vector lacking a splice donor/intron (V179). No splicing occurs in these 
transcripts, 5' – Vector created by recombining a donor lacking a 5' splice acceptor (V7 or V308-based) and a 5' tag acceptor 
vector lacking a splice donor/intron (V516- Double Myc, V179 – Triple Flag). No splicing occurs in these transcripts, SPLICE – 
Expression vector created by recombining a Creator Splice donor (5' splice acceptor – V37-based) and a Creator Splice 5' tag 
acceptor vector containing a splice donor/intron (V517 – Double Myc, V180 – Triple Flag). Resulting transcripts undergo splic-
ing at the 5' end to remove the loxP sequence and juxtapose the tag onto the ORF, 3' – Vector created by recombining a 
donor lacking a 5' splice acceptor (V7 or V308-based) with a 3' tag acceptor vector lacking a splice donor/intron (V518 – Dou-
ble Myc, V181 – Triple Flag). Splicing only occurs at the 3' end to remove the CmR gene (The donor contains a splice donor 
preceding the CmR ORF and the acceptor vector contains a splice acceptor preceding the tag), 3' SA – Vector created by 
recombining a Creator Splice donor vector containing a 5' splice acceptor (V37-based) and a 3' tag acceptor vector lacking a 
splice donor/intron (V181 -Triple Flag). Splicing only occurs at the 3' end to remove the CmR gene (same as 3' tag) and TOPO 
– 5' tag, non-Creator system.
A) anti-Myc Blots B) anti-Flag Blots
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A) Anti-Flag immunoblot of ArhGap24 with tags in the indicated positions Figure 5
A) Anti-Flag immunoblot of ArhGap24 with tags in the indicated positions. The transfections and expression analyses were 
performed in duplicates (a and b). B) Immunoblot analysis of Nadrin with tags in the indicated position. The top panel was 
probed with anti-Flag antibody. The immunoblot was then stripped of antibody and reprobed with anti-Nadrin (bottom panel). 
C) Quantitative analysis of protein levels for six different proteins with Triple-Flag epitope tags at the indicated positions. For 
each replicate, the band intensity, as detected by Flag M2 antibody, was normalized by the transfection efficiency as detected by 
fluorescent values of a co-transfecting plasmid pLP ECFP C1. The normalized band intensity was then average between the two 
replicates. Ratios of each tagged-protein relative to the protein expressed from the same ORF from the TOPO vector are 
shown above the bars. Abbreviations: SPLICE – Creator Splice Donor (V37-based) and Creator Splice 5' acceptor (V180) – 
splicing occurs at 5' end, 5' – standard Clontech system (donor – V7-based and acceptor – V179) – no splicing at either end, 3' 
– standard Clontech system (donor – V7-based and acceptor – V181) – splicing at 3' end to remove the CmR gene, 5' SA, Cre-
ator Splice Donor (V37-based) and 5' acceptor vector (V179) – no splicing at either end, TOPO – 5' tag non-recombination 
system, CNT – counts, RFU – relative fluorescent units.
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affect translation by interfering with 40S ribosomal subu-
nit binding [45].
While many assays do not require or are compromised by
high expression levels, it is often easier to reduce expres-
sion levels than raise them. This reduction can be accom-
plished by using a weaker promoter or by transfecting less
DNA. However, it is often not feasible to transfect suffi-
cient DNA required to achieve high expression levels or to
improve the promoter to compensate for low expression.
Most of our assays benefit from high expression levels.
Intracellular assays such as the Mito tracker require high
levels of expression for visualization of the fluorescent
protein in the cell and to sufficiently pull associated pro-
teins to the mitochondria to induce a phenotype. For
mass spectrometry or Lumier analysis ([26], high levels of
expression are key to reducing the amount of starting
material. This reduction decreases cost and increases
throughput. In addition, it has been our experience that
weak epitope tags (such as a Single-Flag epitope) require
the increased expression of our Creator Splice system for
routine visualization of proteins by immunoblot analysis
(see additional file 5C). The disadvantage of the Creator
Splice system is that it requires an additional donor vector
and customized acceptor vectors. This disadvantage is
relieved to some extent however, because inserts flanked
by AscI and PacI sites can be easily swapped between the
two donors without having to perform additional DNA
sequencing.
Conclusion
We have modified the Creator system by extending the
multiple cloning sites of the donor vectors, creating a
repository of downstream vectors, and by increasing
expression levels with the Creator Splice system that
allows for splicing at the 5' end. Investigators using this
system have full control to develop constructs with high
expression yet control the tag and linker sequences to
maintain or optimize protein function. Our system is
designed to facilitate proteomic applications and the
determination of protein functions in cell-based model
systems. These reagents are available to the scientific com-
munity upon request, and it is our hope to build up a set
of reagents that can become a strong resource.
Methods
Production of Cre recombinase
Cre recombinase was purchased from Clontech or puri-
fied in our laboratory as a His-Cre construct (gift from
Paul Sadowski [46]). To purify His-Cre, BL21 cells were
grown in 600 ml LB broth plus 100 µg/ml ampicillin to an
OD600 of 0.5, induced with 1 mM IPTG, and allowed to
grow for another 4 hours. Cells were pelleted and lysed
using a cell homogenizer in lysis buffer (50 mM TrisHCl
pH8, 300 mM NaCl, 100 mM PMSF). The lysate was clar-
ified by centrifugation (20,000 × G for 20 minutes) and
the supernatant was loaded onto a 5 ml Ni-Nta column
(Amersham). The column was washed with 50 mM
TrisHCl pH8, 600 mM NaCl, 80 mM Imidazole, and 100
mM PMSF and the protein was eluted in 1 ml fractions
using a step-wise gradient starting with wash buffer and
ending with elution buffer of 20 mM TrisHCl pH8, 300
mM NaCl, 100 mM PMSF, and 500 mM Imidazole. Posi-
tive fractions were pooled, and concentrated using a cen-
trifugal filter (centricon, 5 kDa cutoff, Millipore) into a
final solution of 20 mM TrisHCl pH8, 50 mM NaCl, 500
µM EDTA, 1 mM DTT and 50% glycerol.
Vector construction
Specific details on the cloning of each parent vector are
provided in Additional Files 1 (donor vectors) and 2
(acceptor vectors). Sequences of oligonucleotides are pro-
vided in Additional File 4. Full sequences of vectors are
provided online at the Pawson laboratory website ([47]).
Vectors were modified by one of four methods: 1) PCR
and restriction enzyme: inserts were amplified by PCR
using Expand polymerase (Roche), the insert and vector
were digested with the appropriate restriction enzymes,
and ligated together using T4 DNA ligase; 2) PCR and
recombination: inserts were amplified by PCR using
Expand polymerase and recombined into the vector using
In Fusion (Clontech) according to the manufacturers
instructions; 3) Oligonucleotide hybridization: comple-
mentary oligonucleotides (Sigma) were annealed and
ligated into digested-vector, 4) Site-directed mutagenesis:
mutations were introduced into the vector during PCR
amplification of the entire vector using complementary
oligonucleotides (Sigma) with the appropriate mutations
(Quickchange, Stratagene). To create V678 and V795, the
NotI sites in V308 and V309, respectively, were converted
to FseI sites by digesting with NotI, filling in overhangs
with Klenow DNA polymerase and then re-ligating the
vector. All inserts into vectors were sequenced to ensure
their integrity. Acceptor vectors were created using Clon-
tech acceptor backbones (pLP ECFP C1 or pLPS-3'EGFP)
or by adding the loxP-promoter cassette to pre-existing
vectors (Clontech manual PT3576-1). The RFP template
for vectors V1662 to V1664 was modified from the Clon-
tech dsRED2 construct using site-directed mutagenesis to
incorporate 73 single point mutations (resulting in 36 dif-
ferent amino acids) as outlined [19,18].
Chemically treated competent cell preparation
Preparation of highly-competent E. coli cells was based on
the method devised by Inoue [48]. Briefly, 250 ml of cells
were grown in SOB media at room temperature until they
reach an OD600 of 0.6 and then were collected by centrif-
ugation at 2500 × G for 10 minutes at 4°C. The cells were
then resuspended in 80 ml of ice-cold TB buffer (10 mM
PIPES, 55 mM MnCl2, 15 mM CaCl2, 250 mM KCl, pHBMC Biotechnology 2006, 6:13 http://www.biomedcentral.com/1472-6750/6/13
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6.7), incubated on ice for 10 minutes, and the cells were
collected once more by centrifugation at 2500 × G for 10
minutes at 4°C. The cells were resuspended in 20 ml ice-
cold TB buffer and DMSO was added to a final concentra-
tion of 7%. After a further ten minute incubation on ice,
the cells were flash-frozen and stored at -80°C.
ORF cloning and recombination reactions
Additional File 3 outlines details on ORF cloning. Inserts
were cloned using DNA ligase or topoisomerase. For liga-
tion reactions, the ORFs were amplified by PCR, digested
with AscI and PacI and cloned into AscI/PacI-digested vec-
tor. For topoisomerase – inserts were amplified by PCR
using Platinum PFx (Invitrogen) and subcloned into a
CMV5-based directional TOPO vector with a 5' Triple-Flag
sequence ([26]). For recombination reactions, 400 ng of
donor and acceptor were recombined in a final volume of
20 µl for 15 minutes at room temperature in the presence
of Cre recombinase and either optimized recombinase
buffer (5 mM TrisHCl pH7.9, 3.3 mM NaCl, 1 mM MgCl2
and 1 mM spermidine) or standard recombinase buffer
(50 mM TrisHCl pH7.9, 33 mM NaCl, 10 mM MgCl2)
according to Clontech manual PT3460-1. Cre recombi-
nase was inactivated by incubation of the reaction at 70°C
for 10 minutes. Competent cells (> 1 × 108 cfu/µg) were
transformed with 1 µl of the reaction and the entire trans-
formation was plated onto LB-agar plates containing 30
µg/ml chloramphenicol and 7% sucrose (w/v) to select for
the correct recombinant vector. Typical colony numbers
for this reaction are between 5 and 100 colonies.
Immunoblot analysis
HEK293T cells were grown in 6 well dishes in DMEM
media supplemented with 10% fetal calf serum
(HyClone) and transfected by Polyethylenimine (PEI)
using 4 µg of DNA and 10 µg PEI/well [49]. For quantita-
tion of protein expression levels, the cells were co-trans-
fected with V3 (pLP ECFP C1) at 1 µg/well. After 48 hours,
the cells were lysed in NP40 lysis buffer (20 mM TrisHCl
pH8, 137 mM NaCl, 10% Glycerol, 1% NP40, 10 µg/ml
of aprotinin, 10 µg/ml of leupeptin and 1 mM Phenyl-
methylsulphonylfluoride (PMSF)), and the supernatants
clarified by centrifugation at 18,000 × G for 15 minutes.
For quantitation of protein expression, the cell lysate was
divided between immunoblot analysis and fluorescence
analysis. For immunoblot analysis, cell lysates were sepa-
rated by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred to Polyscreen
polyvinylidene fluoride (PVDF) (PerkinElmer), and
blocked in tris-buffered saline with 0.05% tween (TBST)-
containing 5% skim milk powder. Membranes were
probed with the indicated antibodies (0.5 µg/ml M2-Flag
(Sigma) or 1 µg/ml 9E10 (anti-Myc, Santa Cruz)) in TBST-
containing 5% skim milk powder as previously described
[50]. Results were visualized either by exposure to film or
with a Fluor-S-Max instrument (BioRad). For the α-
Nadrin reprobe, the immunoblot was stripped of anti-
body by incubating in stripping buffer (150 mM TrisHCl
pH6.8, 2% SDS, and 100 mM beta-mercaptoethanol) at
65°C for 20 minutes. The immunoblot was then washed
in TBS and blocked in TBST containing 5% skim milk
powder. The blot was then reprobed using α-Nadrin anti-
body (1:1000). Antibodies against Nadrin/Rich1 (#2104)
were generated against bacterially expressed His-tagged
fusion protein of a.a. 1–245 of human Rich1, in the
PET30B expression vector, in Rabbits as described[51].
For quantitation, band intensity, after immunoblot anal-
ysis with the appropriate antibody, was determined by the
Fluor-S-Max software. To determine fluorescent levels of
lysate co-transfected with V3 (pLP ECFP C1), cell lysate
was added to a 96 well quartz plate and the lysate was ana-
lyzed for fluorescence intensity using a spectrum scan
from OD450 to OD520 with excitation at OD433and a cutoff
at OD455 using a SpectroMax Gemini (Molecular Devices).
Subsequent analysis used fluorescent intensity values at
OD480. To determine the relative expression of each vec-
tor, the band intensity of a construct was divided by the
relative fluorescent value of the ECFP expression control
(V3) and this value was averaged between replicates.
Immunofluorescence
NIH 3T3 cells (ATCC) were plated on coverslips in 6 well
dishes in DMEM media supplemented with 10% fetal calf
serum (HyClone). Cells were transfected using lipo-
fectamine 2000 (Invitrogen) according to the manufactur-
ers protocol. After 24 hours, cells were fixed in 4%
paraformaldehyde in phosphate-buffered saline (PBS) for
ten minutes and then permeabilized in 0.3 % Triton X-
100 for five minutes. Cells were then incubated overnight
with a mixture of primary antibodies containing rabbit-
anti-GFP (AbCAM) at 1:200 dilution and mouse-anti-
Cytochrome C (BD Pharmingen) at 0.1 µg/ml. Samples
were extensively rinsed with PBS and subsequently
labeled with a mixture of secondary antibodies containing
goat-anti-mouse Texas Red and goat-anti-rabbit Alexa 488
at 20 µg/ml (Molecular Probes) for one hour. After incu-
bation, and rinses with PBS, Hoechst 33258dye (Molecu-
lar Probes) was added at a 1:1000 dilution to label nuclei
and slides were mounted in Geltol (Fisher Scientific).
Samples were then imaged on a Deltavision Deconvolu-
tion Microscope (Applied Precision Inc., Issaquah, WA)
using an Olympus 100× (N.A. 1.35) objective lens and
raw images were subsequently deconvolved.
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